Risk Assessment of Neurologic Toxicity From Cancer Treatment

Abstract

Neurologic toxicity represents a significant and increasingly recognized complication associated with diverse cancer treatments, including chemotherapy, immunotherapy, radiotherapy, and targeted agents. This review synthesizes current evidence on the risk assessment of neurologic toxicity, highlighting epidemiological trends, pathophysiological mechanisms, clinical risk factors, diagnostic strategies, and management approaches. Recent advances in biomarker discovery, neuroprotective interventions, and guideline-based recommendations are discussed, with a focus on optimizing patient outcomes while minimizing neurotoxic risk. The article underscores the importance of individualized risk stratification and multidisciplinary collaboration in the prevention and management of neurotoxicity in oncology practice.

Introduction

Neurologic toxicity, encompassing a broad spectrum of central and peripheral nervous system complications, is a well-documented adverse effect of modern cancer therapies. As oncologic treatments become increasingly effective and complex, the incidence and diversity of neurologic complications have risen, posing significant challenges for clinicians. Early identification and risk stratification are essential to balance therapeutic efficacy with quality of life. This review provides a comprehensive overview of risk assessment strategies for neurologic toxicity, integrating recent clinical insights and evidence-based guidelines tailored for healthcare professionals.

Epidemiology / Disease Burden

The true incidence of neurologic toxicity among cancer patients is difficult to ascertain, varying according to treatment modality, cancer type, and patient population. Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 68% of patients within the first month of treatment, with agents such as platinum compounds, taxanes, and vinca alkaloids posing the highest risk. Immune checkpoint inhibitors can lead to neurologic immune-related adverse events (n-irAEs) in 1-12% of treated patients, including encephalitis, myasthenia gravis, and demyelinating syndromes. Radiotherapy, particularly cranial or spinal irradiation, is associated with both acute and delayed neurotoxicity, manifesting as cognitive impairment, myelopathy, or cranial neuropathies. The rising use of novel targeted therapies and cellular immunotherapies, such as CAR T-cell therapy, has introduced additional neurotoxicity risks, including cytokine release syndrome-associated encephalopathy. The cumulative burden of neurologic toxicity not only affects functional status and survivorship but also impacts treatment adherence and overall prognosis.

Pathophysiology

The mechanisms underlying neurologic toxicity from cancer treatment are multifactorial, involving direct neuronal injury, immune-mediated inflammation, vascular compromise, and metabolic derangements. Chemotherapeutic agents often induce axonal degeneration or demyelination via disruption of microtubule function, DNA damage, or mitochondrial toxicity. Immune checkpoint inhibitors trigger aberrant immune activation against neural antigens, leading to inflammatory neuropathies and encephalopathies. Radiation-induced injury occurs through endothelial damage, blood-brain barrier disruption, and delayed neuroinflammation, culminating in white matter loss and gliosis. Targeted therapies may interfere with critical neural signaling pathways or ion channel function, further contributing to neurotoxicity. Understanding these mechanisms is crucial for risk stratification and the development of neuroprotective strategies.

Risk Factors

Risk factors for neurologic toxicity are diverse, encompassing patient-specific, disease-related, and treatment-specific variables. Advanced age, pre-existing neurologic conditions, diabetes mellitus, renal or hepatic impairment, and genetic polymorphisms in drug-metabolizing enzymes heighten susceptibility. High cumulative doses, rapid infusion rates, and combination regimens increase neurotoxic risk. Certain tumor types, such as multiple myeloma or lymphoma, are associated with higher incidences of neurotoxicity due to both disease and treatment effects. Pharmacogenomic studies have identified genetic variants (e.g., CYP2C8, ABCB1) that modulate drug disposition and toxicity, underscoring the potential for personalized risk assessment.

Clinical Features

Neurologic toxicity presents with a heterogeneous array of symptoms, depending on the affected neural compartment and causative agent. Peripheral manifestations include symmetric distal sensory loss, paresthesias, neuropathic pain, and motor weakness, as seen in CIPN. Central nervous system involvement may manifest as cognitive dysfunction, seizures, movement disorders, encephalopathy, or focal deficits. Immune-mediated toxicities can present acutely or subacutely, with features such as myasthenia gravis-like weakness, polyradiculoneuropathy, or autoimmune encephalitis. Prompt recognition of these clinical patterns is essential for timely intervention and mitigation of irreversible damage.

Diagnosis

Diagnosis relies on a combination of clinical vigilance, neurophysiological testing, laboratory evaluation, and neuroimaging. Electromyography and nerve conduction studies are invaluable in documenting the pattern and severity of peripheral neuropathy. Lumbar puncture and cerebrospinal fluid analysis may be warranted in suspected immune-mediated or infectious complications. Magnetic resonance imaging (MRI) of the brain and spinal cord is critical for excluding structural lesions, demyelination, or treatment-related leukoencephalopathy. Emerging biomarkers, including neurofilament light chain and glial fibrillary acidic protein, offer promise for early detection and monitoring of neurotoxicity.

Treatment & Management

Management of neurologic toxicity involves prompt discontinuation or dose modification of the offending agent, symptomatic therapy, and multidisciplinary care. Pharmacologic interventions for CIPN include anticonvulsants, antidepressants, and topical agents, though efficacy remains limited. High-dose corticosteroids, intravenous immunoglobulin, or plasmapheresis may be indicated for severe immune-mediated toxicities. Supportive measures, rehabilitation, and patient education are integral to optimizing functional recovery. Emerging evidence supports the use of neuroprotective agents, such as duloxetine for CIPN, and early initiation of immunosuppressive therapy for n-irAEs, to improve outcomes.

Recent Advances / Emerging Therapies

Recent advances in the field focus on the identification of predictive biomarkers, refinement of neuroimaging modalities, and development of targeted neuroprotective strategies. Pharmacogenomic profiling enables identification of high-risk individuals, facilitating tailored dosing and drug selection. Novel agents, including monoclonal antibodies and small-molecule inhibitors with improved safety profiles, are under investigation. Remote digital monitoring and artificial intelligence-driven risk models have shown promise in early detection of neurologic complications. Ongoing clinical trials are evaluating interventions such as sodium channel blockers, antioxidants, and neurotrophic factors for prevention and mitigation of neurotoxicity.

Guideline Recommendations

Contemporary guidelines from the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) emphasize individualized risk assessment, baseline neurologic evaluation, and longitudinal monitoring of at-risk patients. Routine use of validated symptom scales, such as the Common Terminology Criteria for Adverse Events (CTCAE), is recommended for standardized assessment. Early involvement of neurology specialists and integration of supportive and rehabilitative services are critical components of comprehensive care. Where feasible, dose reduction, alternative regimens, or neuroprotective co-therapy should be considered for high-risk patients.

Conclusion

Neurologic toxicity remains a formidable challenge in the era of precision oncology, with significant implications for patient quality of life and therapeutic outcomes. Robust risk assessment protocols, mechanistic understanding, and guideline-concordant management are pivotal to minimizing neurotoxic complications. Continued research into predictive biomarkers, novel therapeutics, and multidisciplinary approaches will further enhance the safety and efficacy of cancer treatment, ultimately improving the neurologic health of oncology patients.